尿素循環障礙治療市場 - 全球產業規模、佔有率、趨勢、機會和預測（按酵素缺乏類型、治療類型、給藥途徑、分銷管道、地區和競爭格局分類），2021-2031年

全球尿素循環障礙治療市場預計將從2025年的5.6016億美元成長到2031年的6.8778億美元，複合年成長率（CAGR）為3.48%。該市場主要針對罕見遺傳性疾病的治療，這些疾病會導致體內氮代謝功能受損，造成危險的氨積累。主要治療方法包括脫氮、胺基酸替代療法和酵素替代療法，旨在清除氨並恢復代謝穩定性。市場成長的主要驅動力是新生兒篩檢和先進基因檢測的廣泛應用，這使得快速且準確的診斷成為可能。根據美國國家尿素循環障礙基金會（NUCDF）2024年的報告，這些疾病的盛行率估計約為每35,000名新生兒中就有1例，這凸顯了需要終身護理的龐大患者群體的存在。

儘管臨床治療取得了進展，但由於孤兒藥價格高昂以及核准流程複雜，市場仍面臨許多障礙。這些經濟和程序上的障礙會嚴重限制患者獲得必要治療的機會，對醫療基礎設施造成沉重的經濟負擔，並可能阻礙資源匱乏地區更廣泛的市場接受度。因此，儘管科學不斷進步，經濟因素仍然是公平獲得治療和更廣泛市場應用的一大挑戰。

市場促進因素

基因療法和基於mRNA的干涉技術的興起正在改變全球尿素循環障礙治療市場，使其不再局限於症狀管理，而是有望實現治癒。這些先進技術旨在恢復肝酵素功能，從而使氨水平正常化，並預防神經認知功能下降，而無需終身飲食限制或肝臟移植。近期臨床數據支持了這些基因藥物的療效，也為這項技術進步提供了佐證。例如，2025年6月，Arcturus Therapeutics公佈了其mRNA候選藥物ARCT-810的II期中期數據，結果顯示，在鳥胺酸氨甲醯基轉移酶缺乏症患者中，第五次給藥後相對尿素功能（RUF）顯著改善了43.7%。這推動了針對潛在遺傳病因的生物製藥的投資增加，並提升了市場預期。

與這些技術創新同步，一系列新型療法的研發管線和正在進行的臨床試驗正在迅速擴大支持疾病長期管理的證據基礎。製藥公司優先考慮產生持續的安全性和有效性數據，以促進監管部門的核准和更廣泛的患者群體獲得市場准入。 2025年8月，Imedica Pharma發表了兩項國際研究的長期追蹤結果，這兩項研究共納入45名患者，結果顯示Lorgys（pegdilarginase）在五年內可提供持續的臨床效益，包括改善運動功能。然而，將這些特殊療法推向市場仍面臨挑戰。 2025年11月，Zebra Therapeutics指出，自Olprava上市以來，該公司僅收到30份處方登記表，凸顯了在超罕見疾病領域，患者識別和市場滲透方面仍然面臨的挑戰。

市場挑戰

全球尿素循環障礙治療市場面臨巨大的成長抑制因素，孤兒藥價格高昂和法規環境複雜是限制因素，嚴重阻礙了患者獲得治療和商業性永續性。脫氮和酵素替代療法的高昂成本常常引發保險公司和醫療支付方的抵制，這些挑戰阻礙了市場擴張。當高昂的成本導致報銷政策限制時，資源匱乏地區的患者將無力承擔必要的終身治療方法，從而導致患者群體萎縮，並抑制了生產商的產生收入。

此外，罕見疾病藥物研發所需的嚴格臨床試驗通訊協定增加了研發者的財務風險，迫使他們提高定價以回收投資。由於目標患者群有限，難以回收研發成本，這種經濟壓力尤其突出。根據美國藥品研究與製造商協會（PhRMA）預測，到2024年，一種新藥上市的平均成本約為26億美元，研發週期通常超過10年。如此龐大的資金需求阻礙了新進業者進入該市場，並減緩了全球尿素循環障礙治療市場創新治療方法的普及。

市場趨勢

由於傳統脫氮劑口感不佳，導致患者治療順從性差，因此，市場格局正因新型掩味口服製劑的研發而重塑。這一趨勢包括無味液體製劑及其學名藥的商業化，顯著減輕了患者日常飲食管理的負擔。這些創新對於維持慢性病治療的依從性至關重要，同時也透過提供更經濟實惠的選擇，促進了市場擴張。 2025年10月，Endo宣佈在美國推出首個獲得FDA核准的RAVICTI（苯丁酸甘油酯）非專利口服液體製劑，使更多僅靠飲食難以控制血氨水平的患者能夠獲得這種重要的氮結合療法。

同時，專注於罕見疾病藥物創新的策略聯盟正透過生物技術公司與患者權益倡導組織之間的合作，彌合診斷方面的差距。這些合作旨在發現未被充分診斷​​的患者群體，例如晚髮型病例和誤診嬰兒，從而擴大符合特殊治療條件的用戶層。透過利用區域網路，這些聯盟提高了公眾對疾病的認知，鼓勵及時進行代謝檢測，並在降低高氨血症相關死亡率方面發揮至關重要的作用。為了強調這一緊迫性，美國國家尿素循環障礙基金會於2025年10月宣布，高達20%的嬰兒猝死症候群（SIDS）病例可能由未確診的先天性篩檢缺陷引起，並呼籲業界廣泛合作，對這些疾病進行篩檢。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球尿素循環障礙治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 酵素缺乏類型（氨甲醯磷酸合成酶 (CPS1)、N-麩胺酸合成酶 (NAGS)、鳥氨酸轉氨甲醯酶 (OTC 缺乏症)、精氨琥珀酸合成酶 (AS)、精氨琥珀酸解離酶(AL 或 ASA解離酶)、精氨酸酶 (AG)）
  • 依治療類型（胺基酸製劑、苯丁酸、苯甲酸鈉、其他）
  • 依給藥途徑（口服與靜脈注射）
  • 按分銷管道（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美尿素循環障礙治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲尿素循環障礙治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區尿素循環障礙治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲尿素循環障礙治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲尿素循環障礙治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球尿素循環障礙治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bausch Health Companies Inc.
• Recordati Rare Diseases
• Eurocept Pharmaceuticals Holding
• Acer Therapeutics
• Ultragenyx Pharmaceutical
• Aeglea BioTherapeutics
• Arcturus Therapeutics, Inc.
• Orpharma Pty Ltd.
• Selecta Biosciences, Inc.
• Abbott Laboratories, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Urea Cycle Disorders Treatment Market is projected to expand from USD 560.16 Million in 2025 to USD 687.78 Million by 2031, registering a compound annual growth rate (CAGR) of 3.48%. This market sector covers therapeutic measures aimed at controlling rare genetic disorders characterized by the body's inability to process nitrogen, leading to dangerous ammonia buildup. Core treatments include nitrogen scavengers, amino acid supplementation, and enzyme replacement therapies intended to aid ammonia removal and reestablish metabolic stability. A primary factor driving market growth is the broad adoption of comprehensive newborn screening and sophisticated genetic testing, which enables prompt and precise diagnosis. As reported by the National Urea Cycle Disorders Foundation in 2024, the prevalence of these conditions was approximately 1 in 35,000 births, highlighting a vital patient group necessitating lifelong care.

Despite clinical progress, the market faces significant hurdles due to the exorbitant costs associated with orphan drugs and the intricate regulatory pathways required for approval. These financial and procedural barriers can severely restrict patient access to essential therapies and place heavy economic strain on healthcare infrastructures, which may impede wider market acceptance in resource-constrained regions. Consequently, economic factors remain a persistent challenge to equitable treatment availability and broader market adoption despite scientific advancements.

Market Driver

The Global Urea Cycle Disorders Treatment Market is undergoing a transformative shift toward potential cures, driven by the rise of gene therapy and mRNA-based interventions, moving beyond mere symptom management. These advanced technologies seek to reinstate functional liver enzyme activity, thereby normalizing ammonia levels and preventing neurocognitive decline without the need for lifelong dietary restrictions or liver transplantation. This technological progress is supported by recent clinical data validating the efficacy of these genetic medicines. For instance, Arcturus Therapeutics reported in June 2025 that interim Phase 2 data for their mRNA candidate, ARCT-810, showed a statistically significant improvement in relative ureagenesis function (RUF) to 43.7% following the fifth dose in patients with ornithine transcarbamylase deficiency, fueling increased investment and market anticipation for biologics targeting the underlying genetic causes.

Alongside these technological innovations, a strong pipeline of new therapeutics and ongoing clinical trials is rapidly broadening the evidence base supporting long-term disease management. Pharmaceutical companies are prioritizing the generation of durable safety and efficacy data to facilitate regulatory approval and market entry for wider patient populations. In August 2025, Immedica Pharma released long-term follow-up results from two international studies involving 45 patients, demonstrating that Loargys (pegzilarginase) offered sustained clinical advantages, such as enhanced mobility, over five years. However, bringing these specialized treatments to market remains difficult; Zevra Therapeutics noted in November 2025 that only 30 prescription enrollment forms had been received for Olpruva since its launch, underscoring the enduring difficulties of patient identification and market penetration within the ultra-rare disease sector.

Market Challenge

The Global Urea Cycle Disorders Treatment Market faces significant growth obstacles due to the high pricing of orphan drugs and a complicated regulatory environment, which create substantial barriers to patient access and commercial sustainability. These challenges impede market expansion because the steep costs of nitrogen scavengers and enzyme replacement therapies frequently result in pushback from insurance providers and healthcare payers. When reimbursement policies are restrictive due to these high expenses, patients in lower-resource settings often cannot afford necessary lifelong treatment regimens, which effectively shrinks the addressable patient base and stalls revenue generation for manufacturers.

Additionally, the strict clinical trial protocols required for rare diseases heighten the financial risks for developers, forcing them to set premium prices to recoup their investments. This economic pressure is particularly acute given the challenge of recovering development costs from a limited target population. According to the Pharmaceutical Research and Manufacturers of America, the average cost to bring a new medicine to market in 2024 was roughly $2.6 billion, with the development timeline often exceeding ten years. This massive capital requirement deters new market entrants and delays the availability of innovative therapies within the Global Urea Cycle Disorders Treatment Market.

Market Trends

The market is being reshaped by the development of taste-masked oral formulations, which address the issue of treatment adherence caused by the unpalatable nature of conventional nitrogen scavengers. This trend involves the commercialization of flavorless, liquid-based agents and their generic counterparts, significantly easing the daily burden of dietary management for patients. These innovations are crucial for maintaining compliance in chronic care while also expanding market reach through more affordable options. In October 2025, Endo announced the launch of the first FDA-approved generic version of RAVICTI (glycerol phenylbutyrate) oral liquid in the United States, thereby increasing access to a vital nitrogen-binding therapy for individuals unable to manage ammonia levels solely through diet.

Concurrently, strategic alliances focused on orphan drug innovation are bridging diagnostic gaps through partnerships between biotechnology firms and patient advocacy groups. These collaborations seek to uncover undiagnosed patient populations, including those with late-onset symptoms or infants previously misdiagnosed, thus expanding the potential user base for specialized therapies. By utilizing community networks, these alliances promote disease awareness initiatives critical for encouraging timely metabolic testing and lowering mortality rates linked to hyperammonemia. Highlighting this urgency, the National Urea Cycle Disorders Foundation stated in October 2025 that up to 20% of sudden infant death syndrome (SIDS) cases might be caused by undiagnosed inborn errors of metabolism, emphasizing the need for broad screening supported by industry cooperation.

Key Market Players

• Bausch Health Companies Inc.
• Recordati Rare Diseases
• Eurocept Pharmaceuticals Holding
• Acer Therapeutics
• Ultragenyx Pharmaceutical
• Aeglea BioTherapeutics
• Arcturus Therapeutics, Inc.
• Orpharma Pty Ltd.
• Selecta Biosciences, Inc.
• Abbott Laboratories, Inc.

Report Scope

In this report, the Global Urea Cycle Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type

• Carbamyl Phosphate Synthetase (CPS1)
• N-Acetylglutamate Synthetase (NAGS)
• Ornithine Transcarbamylase (OTC Deficiency)
• Argininosuccinic Acid Synthetase (AS)
• Argininosuccinate Lyase (AL or ASA Lyase)
• Arginase (AG)

Urea Cycle Disorders Treatment Market, By Treatment Type

• Amino Acid Formulas
• Phenylbutyrate
• Sodium Benzoate
• Others

Urea Cycle Disorders Treatment Market, By Route of Administration

• Oral v/s Intravenous

Urea Cycle Disorders Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Urea Cycle Disorders Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Urea Cycle Disorders Treatment Market.

Available Customizations:

Global Urea Cycle Disorders Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Urea Cycle Disorders Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
  • 5.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
  • 5.2.3. By Route of Administration (Oral v/s Intravenous)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Urea Cycle Disorders Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Enzyme Deficiency Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Urea Cycle Disorders Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Enzyme Deficiency Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Urea Cycle Disorders Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Enzyme Deficiency Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Urea Cycle Disorders Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Enzyme Deficiency Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Urea Cycle Disorders Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Enzyme Deficiency Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Urea Cycle Disorders Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Enzyme Deficiency Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Urea Cycle Disorders Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Enzyme Deficiency Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Enzyme Deficiency Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Enzyme Deficiency Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Enzyme Deficiency Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Urea Cycle Disorders Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Enzyme Deficiency Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Urea Cycle Disorders Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Enzyme Deficiency Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Urea Cycle Disorders Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Enzyme Deficiency Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Enzyme Deficiency Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Enzyme Deficiency Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Enzyme Deficiency Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Urea Cycle Disorders Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Enzyme Deficiency Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Enzyme Deficiency Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Urea Cycle Disorders Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Enzyme Deficiency Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Urea Cycle Disorders Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Enzyme Deficiency Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Urea Cycle Disorders Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Enzyme Deficiency Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Enzyme Deficiency Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Urea Cycle Disorders Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Enzyme Deficiency Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Urea Cycle Disorders Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Enzyme Deficiency Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Urea Cycle Disorders Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bausch Health Companies Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Recordati Rare Diseases
• 15.3. Eurocept Pharmaceuticals Holding
• 15.4. Acer Therapeutics
• 15.5. Ultragenyx Pharmaceutical
• 15.6. Aeglea BioTherapeutics
• 15.7. Arcturus Therapeutics, Inc.
• 15.8. Orpharma Pty Ltd.
• 15.9. Selecta Biosciences, Inc.
• 15.10. Abbott Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer